This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MYOS MYOS RENS Technology (MYOS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About MYOS RENS Technology Stock (NASDAQ:MYOS) 30 days 90 days 365 days Advanced Chart Get MYOS RENS Technology alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.01▼$11.4052-Week Range N/AVolumeN/AAverage Volume1.68 million shsMarket Capitalization$16.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada. Read More Receive MYOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MYOS RENS Technology and its competitors with MarketBeat's FREE daily newsletter. Email Address MYOS Stock News HeadlinesRen Systems Raises $3.5M, Partners With ZoomInfo to Bring AI-powered Relationship Intelligence to Dealmakers at 35,000 BusinessesSeptember 11, 2024 | venturebeat.comVNew Study Evaluates Use of the Nerivio® REN Wearable for Treatment of Migraine in Children Under the Age of 12July 25, 2024 | tmcnet.comHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.July 9 at 2:00 AM | Timothy Sykes (Ad)Ren Zhengfei says US government 'underestimates' HuaweiDecember 23, 2023 | bbc.comBBio-active Peptides Market Size 2023-2031 Industrial Trends by Absolute Reports | with [93 Pages]May 11, 2023 | marketwatch.comLatest "Bio-active Peptides Market" Size Forecast 2023-2031: New Challenges, Drivers, and RestraintsMay 8, 2023 | marketwatch.comBio-active Peptides Market Size Dynamics 2023-2029April 13, 2023 | marketwatch.comGlobal Bio-active Peptides Market: Future Extrapolations and Emerging Updates for 2023-2027March 21, 2023 | marketwatch.comSee More Headlines MYOS Stock Analysis - Frequently Asked Questions How were MYOS RENS Technology's earnings last quarter? MYOS RENS Technology Inc. (NASDAQ:MYOS) issued its earnings results on Tuesday, August, 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.01. The business had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.14 million. MYOS RENS Technology had a negative trailing twelve-month return on equity of 166.68% and a negative net margin of 277.82%. What other stocks do shareholders of MYOS RENS Technology own? Based on aggregate information from My MarketBeat watchlists, some other companies that MYOS RENS Technology investors own include Chesapeake Energy (CHKAQ), Catalyst Pharmaceuticals (CPRX), Ampio Pharmaceuticals (AMPE), Biocept (BIOC), T2 Biosystems (TTOO), AbbVie (ABBV) and Global Blood Therapeutics (GBT). Company Calendar Last Earnings8/06/2019Today7/09/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:MYOS CIK1402479 Webwww.myosrens.com Phone(905) 812-0023FaxN/AEmployees15Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.26 million Net Margins-277.82% Pretax MarginN/A Return on Equity-166.68% Return on Assets-104.95% Debt Debt-to-Equity Ratio0.11 Current Ratio3.78 Quick Ratio1.94 Sales & Book Value Annual Sales$1.03 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / BookN/AMiscellaneous Outstanding Shares12,192,000Free FloatN/AMarket Cap$16.70 million OptionableNot Optionable Beta1.08 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:MYOS) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MYOS RENS Technology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MYOS RENS Technology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.